+

WO2003018019A3 - Nouvelle utilisation de compose cyclique - Google Patents

Nouvelle utilisation de compose cyclique Download PDF

Info

Publication number
WO2003018019A3
WO2003018019A3 PCT/JP2002/008443 JP0208443W WO03018019A3 WO 2003018019 A3 WO2003018019 A3 WO 2003018019A3 JP 0208443 W JP0208443 W JP 0208443W WO 03018019 A3 WO03018019 A3 WO 03018019A3
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
salt
hydrogen
compound
formula
Prior art date
Application number
PCT/JP2002/008443
Other languages
English (en)
Other versions
WO2003018019A2 (fr
Inventor
Takuma Oku
Yoshitaka Hirayama
Kaoru Yamagami
Yoshitaka Ohkubo
Hideaki Matsuoka
Original Assignee
Fujisawa Pharmaceutical Co
Takuma Oku
Yoshitaka Hirayama
Kaoru Yamagami
Yoshitaka Ohkubo
Hideaki Matsuoka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co, Takuma Oku, Yoshitaka Hirayama, Kaoru Yamagami, Yoshitaka Ohkubo, Hideaki Matsuoka filed Critical Fujisawa Pharmaceutical Co
Priority to AU2002313591A priority Critical patent/AU2002313591A1/en
Publication of WO2003018019A2 publication Critical patent/WO2003018019A2/fr
Publication of WO2003018019A3 publication Critical patent/WO2003018019A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un agent comprenant un composé de formule (I-a) et analogue, ou un sel de celui-ci, l'utilisation d'un composé de formule (I-a) et analogue, ou un sel de celui-ci pour la fabrication d'un médicament, ou un procédé comportant l'administration d'un composé de formule (I-a) et analogue, ou un sel de celui-ci, pour le traitement de maladie respiratoire inflammatoire, dans laquelle formule: Aa est un groupe sulfonyle ou carbonyle; R1a est un aryle éventuellement substitué; R2a est hydrogène; R3a est un alkyle inférieur éventuellement substitué; R4a est hydrogène, un alkyle inférieur éventuellement substitué, un aryle éventuellement substitué ou un groupe hétérocyclique éventuellement substitué; R5a est hydrogène; et R6a est un hydroxyle ou un hydroxyle protégé.
PCT/JP2002/008443 2001-08-24 2002-08-21 Nouvelle utilisation de compose cyclique WO2003018019A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002313591A AU2002313591A1 (en) 2001-08-24 2002-08-21 New use of cyclic compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR7262A AUPR726201A0 (en) 2001-08-24 2001-08-24 New use of a cyclic compound
AUPR7262 2001-08-24

Publications (2)

Publication Number Publication Date
WO2003018019A2 WO2003018019A2 (fr) 2003-03-06
WO2003018019A3 true WO2003018019A3 (fr) 2003-12-04

Family

ID=3831215

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/008443 WO2003018019A2 (fr) 2001-08-24 2002-08-21 Nouvelle utilisation de compose cyclique

Country Status (2)

Country Link
AU (1) AUPR726201A0 (fr)
WO (1) WO2003018019A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104926707B (zh) * 2015-05-12 2017-10-27 江苏福瑞生物医药有限公司 一种药物中间体的合成方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020824A1 (fr) * 1995-12-08 1997-06-12 Agouron Pharmaceuticals, Inc. Inhibiteurs de metalloproteinases, compositions pharmaceutiques contenant ces inhibiteurs et leurs utilisations pharmaceutiques, et procedes et intermediaires servant a leur preparation
WO1998008825A1 (fr) * 1996-08-28 1998-03-05 The Procter & Gamble Company Inhibiteurs 1,4-heterocycliques de metalloproteases
WO1998027069A1 (fr) * 1996-12-17 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Composes de piperazine inhibiteurs de metalloprotease matricielle (mmp) ou de tnf
WO1998034918A1 (fr) * 1997-02-11 1998-08-13 Pfizer Inc. Derives de l'acide arylsulfonylhydroxamique
WO2000009492A1 (fr) * 1998-08-12 2000-02-24 Pfizer Products Inc. Inhibiteurs de l'enzyme de conversion du facteur de necrose tumorale alpha (tace)
WO2000044709A2 (fr) * 1999-01-27 2000-08-03 American Cyanamid Company INHIBITEURS D'ENZYME DE CONVERSION DU FACTEUR DE NECROSE TUMORALE α (TACE) CONSISTANT EN DES ACIDES HYDROXAMIQUES DE SULFONAMIDE A BASE D'ACIDE α-AMINE ACETYLENIQUE
EP1081137A1 (fr) * 1999-08-12 2001-03-07 Pfizer Products Inc. Inhibiteurs sélectifs de l'aggrécanase pour le traitement de l'ostéoarthrite
WO2002067866A2 (fr) * 2001-02-27 2002-09-06 Axys Pharmaceuticals, Inc. Nouveaux inhibiteurs de metalloprotease matricielle

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020824A1 (fr) * 1995-12-08 1997-06-12 Agouron Pharmaceuticals, Inc. Inhibiteurs de metalloproteinases, compositions pharmaceutiques contenant ces inhibiteurs et leurs utilisations pharmaceutiques, et procedes et intermediaires servant a leur preparation
WO1998008825A1 (fr) * 1996-08-28 1998-03-05 The Procter & Gamble Company Inhibiteurs 1,4-heterocycliques de metalloproteases
WO1998027069A1 (fr) * 1996-12-17 1998-06-25 Fujisawa Pharmaceutical Co., Ltd. Composes de piperazine inhibiteurs de metalloprotease matricielle (mmp) ou de tnf
WO1998034918A1 (fr) * 1997-02-11 1998-08-13 Pfizer Inc. Derives de l'acide arylsulfonylhydroxamique
WO2000009492A1 (fr) * 1998-08-12 2000-02-24 Pfizer Products Inc. Inhibiteurs de l'enzyme de conversion du facteur de necrose tumorale alpha (tace)
WO2000044709A2 (fr) * 1999-01-27 2000-08-03 American Cyanamid Company INHIBITEURS D'ENZYME DE CONVERSION DU FACTEUR DE NECROSE TUMORALE α (TACE) CONSISTANT EN DES ACIDES HYDROXAMIQUES DE SULFONAMIDE A BASE D'ACIDE α-AMINE ACETYLENIQUE
EP1081137A1 (fr) * 1999-08-12 2001-03-07 Pfizer Products Inc. Inhibiteurs sélectifs de l'aggrécanase pour le traitement de l'ostéoarthrite
WO2002067866A2 (fr) * 2001-02-27 2002-09-06 Axys Pharmaceuticals, Inc. Nouveaux inhibiteurs de metalloprotease matricielle

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHENG M ET AL: "DESIGN AND SYNTHESIS OF PIPERAZINE-BASED MATRIX METALLOPROTEINASE INHIBITORS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, no. 3, 2000, pages 369 - 380, XP000919159, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
AUPR726201A0 (en) 2001-09-20
WO2003018019A2 (fr) 2003-03-06

Similar Documents

Publication Publication Date Title
NZ544009A (en) Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
ZA200603538B (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same
WO2008133273A1 (fr) Composition pharmaceutique pour le traitement de la maladie d'alzheimer
UA85708C2 (ru) Лекарственные комбинации, содержащие бензоксазины, для лечения заболеваний дыхательных путей
IN2015DN01132A (fr)
WO2006034341A3 (fr) Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
SG164375A1 (en) Extended release pellet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
DE60308997D1 (de) Formulierungen zur inhalation
TW200637839A (en) 1-thio-d-glucitol derivatives
WO2004037789A3 (fr) Derives de methylene uree
WO2003037864A1 (fr) Compose indolique, et utilisation a des fins therapeutiques
EP1839662A4 (fr) Agent antitumoral
WO2000068198A3 (fr) Derives de pyridine heterosubstitues utilises comme inhibiteurs de pde 4
WO2003087049A3 (fr) Combinaisons de produits pharmaceutiques contenant des composes heterocycliques et un nouvel anticholinergique
EP1714961A4 (fr) Compos indazole et utilisation pharmaceutique de celui-ci
WO2006067392A3 (fr) Composes
WO2001081316A3 (fr) Inhibiteurs de phenyle farnesyltransferase substitues
EP1669345A4 (fr) Derive d'ester et utilisation medicale de celui-ci
WO2003059878A3 (fr) Composes antiviraux
WO2008136377A1 (fr) Composé hétérocyclique bicyclique
WO2003018019A3 (fr) Nouvelle utilisation de compose cyclique
DE60127535D1 (de) Vorbeugende oder therapeutische mittel gegen gastrische oder ösophageale regurgitation
WO2005053702A3 (fr) Agents anti-inflammatoires
WO2005014576A8 (fr) Derive d'isoquinoline, procede permettant de produire ce derive, et utilisation de ce derive

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载